A kind of cardiovascular stent coating based on double-layer heterogeneous structure and preparation method thereof

Abstract

The invention discloses a preparation method for a cardiovascular stent coating based on a double-layered heterogeneous structure. The preparation method comprises the following steps: 1) constructinga drug coating containing an anti-proliferation drug on a cardiovascular stent; 2) mixing a double-bond terminated polymer with a water-soluble polymer, and dissolving into a solvent; then spraying on the drug coating, and immersing and corroding with water to obtain a porous coating; 3) covering a sulfhydrylated biological macromolecular solution containing a photoinitiator on the surface of theporous coating, and irradiating through ultraviolet light to obtain a heparinization modified porous coating; and finally, loading biological factors to obtain the cardiovascular stent coating. The invention also discloses the cardiovascular stent coating prepared by the method. The method is simple and efficient, and preparation steps are greatly simplified; the prepared coating enables the biological factors to be loaded highly actively, so that growth factors and drugs are compounded to inhibit the intimal hyperplasia, and also promote the rapid repairing of endodermis, and furthermore, abetter vascular tissue reconstruction performance is achieved.

Description

technical field [0001] The invention relates to the field of biomedical materials, in particular to a cardiovascular stent coating based on a double-layer heterogeneous structure and a preparation method thereof. Background technique [0002] Cardiovascular disease (Cardiovascular diseases, CVD) is currently the number one killer threatening human life. According to a survey conducted by the National Center for Cardiovascular Diseases, the number of CVD patients in China is as high as 290 million, among which the number of patients with coronary atherosclerotic heart disease (coronary heart disease) is about 11 million, which has become a major public health problem. Hygiene issue. [0003] With the development of modern medical technology, the implantation of drug-eluting stent (DES) with the function of inhibiting neointimal hyperplasia has become the gold standard for the treatment of cardiovascular diseases. However, with the widespread use of DES, adverse events such ...

AI Technical Summary

Problems solved by technology

However, in the actual clinical comparative study, the Genous stent modified by antibody anti-CD34 did not show the compound expected superior effect compared with the traditional drug-eluting stent

There are many possible reasons. On the one hand, the process of sterilization and storage, which is indispensable in the preparation process of the scaffold, will cause irreversible damage to the bioactive molecules, making some or all of the bioactive molecules invalid, thereby greatly weakening the bioactive molecules. On the other hand, the blood vessel loss caused by the stent implantation will start the body's self-repair mechanism, so the early use of anti-proliferative drugs is indispensable

[0006] In summary, the traditional drug-eluting stent coating delays or even hinders the remodeling of the endothelial layer of blood vessels, thereby increasing the risk of late thrombosis; bioactive molecules with endothelial cell specificity can achieve the purpose of accelerating endothelial layer repair, However, how to deal with the destruction of bioactive molecules in the process of sterilization and storage during scaffold preparation is still full of challenges

More importantly, the use of anti-proliferative drugs in stent coating is inevitable due to the inevitable loss of blood vessels during stent implantation, which stimulates the self-repair mechanism of blood vessels.

Images